Qingsong Zhu, Ph.D., is the Chief Operating Officer of Insilico Medicine. Dr. Zhu received his doctorate in biochemistry from Kansas State University. As part of his studies, he integrated biochemistry, genomics, and bioinformatics to identify new drug targets for insect control. Before joining Insilico, he also served as a research fellow at the Johns Hopkins University School of Medicine under Dr. Nancy Davidson. His research focused on cancer epigenetic biomarkers and anti-epigenetic cancer drug discovery. He is currently interested in using deep learning to promote biomarker development and drug discovery.

Latest insights

Fri Mar 13 2020

Did an experimental drug help a U.S. coronavirus patient?

Fri Jan 10 2020

MoneyBall Medicine: Tom Davenport on the Analytics Gap in Healthcare

Wed Dec 18 2019

MoneyBall Medicine – Milind Kamkolkar on Seeing the Forest and the Tr...

Fri Nov 8 2019

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery

Never miss an announcement